Answers are grounded in this paper and cite their sources.
Anti‐ tumor necrosis factor (TNF) agents are effective in preventing and treating postoperative recurrence (POR) in Crohn's disease (CD), while some patients have intolerance or fail treatment. Ustekinumab may offer an alternative, though data are limited. To compare the efficacy of anti‐TNF agents with ustekinumab for preventing and treating POR in CD. Patients who initiated anti‐TNF agents or ustekinumab within three months after surgery for POR prevention or after ileocolonoscopy with Rutgeerts score ≥ i2 for POR treatment were included. Endoscopic and clinical outcomes were evaluated. For preventing POR, 68 patients received anti‐TNF agents and 34 received ustekinumab, showing no significant differences in endoscopic POR ( p = 0.777). Ustekinumab had a lower rate of clinical POR ( p = 0.004) and biological therapy discontinuation ( p < 0.001). For treating POR, 35 received anti‐TNF agents and 27 received ustekinumab, with no significant differences in endoscopic improvement ( p = 0.632) or remission ( p = 0.285). Ustekinumab showed a higher clinical treatment success ( p = 0.004). Among 12 patients switching to ustekinumab after anti‐TNF failure, 41.7% showed endoscopic remission, and 83.3% achieved clinical treatment success. Ustekinumab has better clinical outcomes and treatment persistence than anti‐TNF agents in preventing and treating endoscopic POR in CD.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: